Patient Journey Protocol

GLP-1 Patient Journey: Semaglutide & Tirzepatide

Overview

GLP-1 (glucagon-like peptide-1) receptor agonists represent a major advance in the treatment of type 2 diabetes and chronic obesity. Semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity) are the two most prescribed agents in this class.[1][2]

This patient journey protocol outlines the complete arc of GLP-1 therapy: from initial candidate screening through titration, maintenance, and potential discontinuation. It is designed as an educational reference for clinicians and informed patients, not as a substitute for individualized medical decision-making.

Pre-Treatment Screening

Required Baseline Labs

  • HbA1c: Establishes glycemic baseline. Essential for diabetic patients; useful for metabolic assessment in obesity patients.
  • Fasting glucose and insulin: Assess insulin resistance (HOMA-IR calculation).
  • Comprehensive metabolic panel (CMP): Renal function (eGFR, creatinine), hepatic function (ALT, AST), electrolytes.
  • Lipid panel: Total cholesterol, LDL, HDL, triglycerides. GLP-1 agonists may improve lipid profiles.[3]
  • Thyroid function (TSH): Screen for thyroid disease before initiation. See contraindications below.
  • Amylase and lipase: Baseline pancreatic enzymes given the (rare) risk of pancreatitis.[4]

Baseline Metrics

  • Body weight, BMI, waist circumference
  • Blood pressure and resting heart rate
  • Body composition (DEXA) if available — useful for tracking lean mass preservation
  • Patient-reported quality of life assessment

Contraindication Screening

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 receptor agonists carry a boxed warning based on thyroid C-cell tumor findings in rodents. Contraindicated in patients with MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[5]

History of pancreatitis. Use with extreme caution. GLP-1 agonists have been associated with rare cases of acute pancreatitis. Discontinue immediately if pancreatitis is suspected.[4]

Severe gastroparesis. GLP-1 agonists delay gastric emptying and may worsen gastroparesis symptoms significantly.

Pregnancy or planned pregnancy. Discontinue semaglutide at least 2 months before planned conception; tirzepatide at least 1 month before. Category X-equivalent based on animal data.[5]

Severe renal impairment (eGFR <15 mL/min). Limited data in this population. Use with caution in moderate impairment.

History of suicidal ideation or severe depression. Post-marketing reports have prompted FDA investigation into potential neuropsychiatric effects. Screen with PHQ-9 at baseline.

Titration Phase

Gradual dose escalation is critical for tolerability. The primary reason patients discontinue GLP-1 therapy is gastrointestinal side effects, which are dose-dependent and significantly reduced by slow titration.[6]

Semaglutide (Wegovy/Ozempic)

Phase Dose Duration
Month 1 0.25 mg/week 4 weeks
Month 2 0.5 mg/week 4 weeks
Month 3 1.0 mg/week 4 weeks
Month 4 1.7 mg/week 4 weeks
Month 5+ 2.4 mg/week Maintenance

Tirzepatide (Zepbound/Mounjaro)

Phase Dose Duration
Month 1 2.5 mg/week 4 weeks
Month 2 5 mg/week 4 weeks
Month 3 7.5 mg/week 4 weeks
Month 4 10 mg/week 4 weeks
Month 5+ 10–15 mg/week Maintenance
Titration Scheduler Tool

Use our GLP-1 Titration Scheduler to generate a personalized week-by-week titration calendar with injection reminders and dose tracking based on the FDA-approved escalation schedules above.

Titration flexibility: If a patient experiences intolerable GI side effects at a given dose, extend that dose level for an additional 2–4 weeks before attempting escalation. There is no requirement to reach the maximum dose; many patients achieve meaningful outcomes at intermediate doses.[6]

GI Side Effect Management

Gastrointestinal effects are the most common adverse events with GLP-1 therapy, occurring in 40–70% of patients during titration. Most symptoms are transient and diminish over 4–8 weeks at a stable dose.[7]

Nausea Management

  • Eat smaller, more frequent meals (5–6 small meals rather than 2–3 large meals)
  • Avoid high-fat and greasy foods, which exacerbate delayed gastric emptying
  • Eat slowly and stop at the first sign of fullness
  • Stay hydrated with clear fluids, ginger tea, or peppermint tea
  • Avoid lying down immediately after eating; wait at least 30 minutes
  • Pharmacological options: Ondansetron (Zofran) 4–8 mg as needed; ginger capsules (250 mg 4x/day); vitamin B6 (25 mg 3x/day)

Other GI Symptoms

  • Constipation: Increase fiber intake gradually, ensure adequate hydration (64+ oz/day), consider osmotic laxatives (MiraLAX) if persistent
  • Diarrhea: Usually transient. Avoid lactose-heavy foods. Loperamide for severe episodes.
  • Acid reflux/GERD: Elevate head of bed, avoid eating 3 hours before sleep, consider OTC antacids or PPI if persistent

Ongoing Monitoring

Every 4 Weeks (During Titration)

  • Weight, blood pressure, heart rate
  • GI symptom assessment (severity scale 1–10)
  • Medication adherence check
  • Injection site examination
  • Mental health screening (brief mood assessment)

Every 3 Months

  • HbA1c: For diabetic patients; also useful to track metabolic improvement in pre-diabetic obesity patients[1]
  • Fasting glucose and insulin
  • Lipid panel
  • CMP: Monitor renal and hepatic function
  • Weight and body composition trends

Every 6 Months

  • Amylase and lipase: Surveillance for subclinical pancreatitis
  • TSH: Thyroid function monitoring
  • Gallbladder assessment: Clinical screening for cholelithiasis symptoms (rapid weight loss increases gallstone risk)[8]
  • Nutritional assessment: Screen for protein, vitamin, and mineral deficiencies due to reduced caloric intake

Patient Self-Monitoring

  • Weekly weight log (same day, same time, same conditions)
  • GI symptom diary (type, severity, timing relative to meals and injection)
  • Food journal (minimum first 3 months) to ensure adequate protein intake (target: 1.0–1.2 g/kg/day)
  • Exercise log

Maintenance Phase

Once a patient reaches their target dose and achieves stable weight loss or glycemic control, the focus shifts to long-term maintenance:

  • Dose optimization: Not all patients need the maximum dose. The maintenance dose is the lowest dose that sustains clinical benefit with acceptable tolerability.
  • Weight plateaus: Weight loss typically plateaus at 12–18 months. This is expected and does not indicate treatment failure. The plateau represents a new metabolic equilibrium.[9]
  • Lean mass preservation: Ensure adequate protein intake and resistance training. GLP-1 agonist-induced weight loss includes ~25–40% lean mass loss in the absence of exercise intervention.[10]
  • Annual comprehensive review: Full metabolic panel, body composition assessment, cardiovascular risk reassessment, and treatment continuation decision.

Discontinuation & Weight Regain

One of the most important counseling points for GLP-1 therapy is the high likelihood of weight regain after discontinuation. The STEP 1 extension trial demonstrated that participants who discontinued semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of their lost weight within one year of stopping.[9]

Weight Regain Evidence

In the STEP 1 trial extension, participants who discontinued semaglutide regained 11.6 percentage points of body weight (of the 17.3% initially lost) within 52 weeks of stopping, along with reversion of cardiometabolic improvements. This suggests GLP-1 therapy may need to be long-term for sustained benefit.[9]

If Discontinuation is Necessary

  • Gradual taper: Step down through reverse titration over 4–8 weeks rather than abrupt discontinuation
  • Intensify lifestyle interventions: Increase structured exercise frequency, engage a dietitian, and consider behavioral therapy
  • Close monitoring: Monthly weight checks for 6 months post-discontinuation
  • Restarting: If significant regain occurs (>5% from nadir), discuss restarting therapy. Re-titration may be needed if off therapy for more than 4 weeks.

Lifestyle Integration

Nutrition

  • Protein priority: 1.0–1.2 g protein per kg body weight daily to preserve lean mass. Eat protein first at each meal.[10]
  • Caloric floor: Despite reduced appetite, ensure minimum ~1,200 kcal/day for women and ~1,500 kcal/day for men to prevent nutritional deficiency
  • Micronutrient supplementation: Consider a multivitamin, and specifically monitor vitamin D, B12, iron, and calcium
  • Meal timing: Regular meal schedule helps manage GI symptoms; avoid skipping meals entirely

Exercise

  • Resistance training: 2–3 sessions per week, essential for lean mass preservation during weight loss
  • Aerobic activity: 150–300 minutes of moderate-intensity activity per week (walking, cycling, swimming)
  • Progressive overload: Gradually increase resistance training volume as fitness improves
  • Avoid overtraining: Reduced caloric intake plus intense exercise can lead to fatigue and injury

When to Contact Your Prescriber

Seek Medical Attention Immediately

Severe abdominal pain that radiates to the back (possible pancreatitis)

Signs of allergic reaction: rash, itching, swelling of face/tongue/throat, difficulty breathing

Signs of hypoglycemia (especially if on concurrent sulfonylurea or insulin): confusion, shakiness, sweating, rapid heartbeat

Vision changes (possible diabetic retinopathy worsening, particularly with rapid A1C reduction)[11]

Persistent vomiting (>48 hours) with inability to keep fluids down — risk of dehydration and acute kidney injury

New or worsening depression, suicidal thoughts, or significant mood changes

Lump or swelling in the neck, difficulty swallowing, or hoarseness (possible thyroid concern)

Also contact your prescriber (non-emergent) for:

  • GI side effects that persist beyond 4–6 weeks at a stable dose
  • Weight loss exceeding 1 kg/week consistently (may indicate excessive caloric restriction)
  • Hair loss (telogen effluvium, common with rapid weight loss)
  • Symptoms of gallbladder disease (right upper quadrant pain after fatty meals)
  • Questions about dose adjustment or titration timing

Video Resources

These videos from trusted educators provide additional context on GLP-1 receptor agonist therapy and metabolic health.

The science behind GLP-1 medications like semaglutide and tirzepatide — Huberman Lab

Nutrition strategies for GLP-1 therapy and body composition — Huberman Lab

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID: 33567185. (STEP 1 trial)
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID: 35658024. (SURMOUNT-1 trial)
  3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141. PMID: 27633186. (SUSTAIN-6 trial)
  4. FDA. Highlights of prescribing information: WEGOVY (semaglutide) injection. Reference ID: 4807651. Revised 2023. Available at: accessdata.fda.gov.
  5. FDA. Highlights of prescribing information: OZEMPIC (semaglutide) injection. Reference ID: 4788028. Revised 2023. Available at: accessdata.fda.gov.
  6. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224. PMID: 33755728.
  7. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0. PMID: 33667417.
  8. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity: a post hoc analysis of the STEP trials. Obesity. 2023;31(2):532-541. doi:10.1002/oby.23673. PMID: 36695058.
  9. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID: 35441470.
  10. Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Network Open. 2021;4(1):e2033457. doi:10.1001/jamanetworkopen.2020.33457. PMID: 33471120.
  11. Vilsboll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism. 2018;20(4):889-897. doi:10.1111/dom.13172. PMID: 29178519.